Acrylamide Quickview (CASRN 79-06-1)

Status of Data for Acrylamide

File First On-Line: 09/26/1988; Last Significant Revision: 01/01/1991

Category (section)	Status	Last Revised
Oral RfD Assessment	On-line	03/01/1991
Inhalation RfC Assessment	Message	11/01/1990
Carcinogenicity Assessment	On-line	07/01/1993
Under Re-Assessment

Synonyms

79-06-1 Acrylamide Acrylic amide Akrylamid Amid kyseliny akrylove

Ethylenecarboxamide Propenamide 2-Propenamide RCRA Waste Number u007 UN 2074

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect	Point of Departure*	UF	MF	RfD
Nerve damage	NOEL : 0.2 mg/kg-day	1000	1	2 x10-4 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Oral RfD)
  • Rat subchronic drinking water study, Burek et al., 1980
• Confidence in the Oral RfD
  • Study -- High
  • Database -- Medium
  • RfD -- Medium

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Information reviewed but value not estimated. See IRIS Summary.

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)
• Weight-of-Evidence Narrative:
  • Based on inadequate human data and sufficient evidence of carcinogenicity in animals; significantly increased incidences of benign and/or malignant tumors at multiple sites in both sexes of rats, and carcinogenic effects in a series of one-year limited bioassays in mice by several routes of exposures. The classification is supported by positive genotoxicity data, adduct formation activity, and structure-activity relationships to vinyl carbamate and acrylonitrile.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Oral Slope Factor(s)	Extrapolation Method
4.5 per mg/kg-day	Linearized multistage procedure, extra risk

Drinking Water Unit Risks
1.3x10-4 per ug/L

Risk Level	Concentration
E-4 (1 in 10,000)	8x10-1 ug/L
E-5 (1 in 100,000)	8x10-2 ug/L
E-6 (1 in 1,000,000)	8x10-3 ug/L

• Dose-Response Data (Carcinogenicity, Oral Exposure)
  • Tumor Type: CNS, mammary and thyroid glands, uterus, oral cavity (combined)
  • Test Species: Rat/Fischer 344, female
  • Route: Oral, drinking water
  • Reference: Johnson et al., 1986

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Inhalation Unit Risk(s)	Extrapolation Method
1.3 x10-3 per ug/m3	Linearized multistage procedure, extra risk

Inhalation Concentrations at Specified Risk Levels

Risk Level	Concentration
E-4 (1 in 10,000)	8x10-2 ug/m3
E-5 (1 in 100,000)	8x10-3 ug/m3
E-6 (1 in 1,000,000)	8x10-4 ug/m3

• Dose-Response Data (Carcinogenicity, Inhalation Exposure)
  • Tumor Type: CNS, mammary and thyroid glands, uterus, oral cavity (combined)
  • Test Species: Rat/Fischer 344, female
  • Route: Oral, drinking water
  • Reference: Johnson et al., 1986